Key result
Dapagliflozin yields an ICER of ~$5,946 per QALY gained over standard HFrEF care in Colombia.
Why the study?
Although DAPA-HF demonstrated clinical benefits with dapagliflozin in heart failure with reduced ejection fraction, its cost-utility from the perspective of the Colombian health system was unknown.
Does dapagliflozin added to standard treatment improve cost-utility compared to standard treatment alone in patients with heart failure with reduced ejection fraction in Colombia?
Does dapagliflozin added to standard treatment improve cost-utility compared to standard treatment alone in patients with heart failure with reduced ejection fraction in Colombia?
Dapagliflozin added to standard therapy is a cost-effective option for the management of HFrEF within the Colombian healthcare system.
Answers are grounded in this paper and cite their sources.
Supports dapagliflozin reimbursement for HFrEF in Colombia at $5,946/QALY; extends DAPA-HF data to local payer modeling.
INTRODUCTION: The DAPA-HF study has shown that dapagliflozin added to standard treatment reduced the risks of worsening of heart failure or cardiovascular death compared to placebo. OBJECTIVES: To evaluate the cost- utility of dapagliflozin in combination with standard treatment compared to standard treatment alone for the treatment of heart failure with reduced ejection fraction from the perspective of the Colombian health system. METHODS: A Markov model using information from the DAPA-HF study was adapted to the Colombian setting. Health states considered symptom score, and transient health states were included to assess the incidence of consultations and hospitalizations for heart failure. The time horizon was 5 years and a 5% discount rate was applied. The costs were expressed in US dollars of 2020 (1 USD =$3,693.36 COP). RESULTS: The incremental cost-effectiveness ratio (ICER) of the intervention compared to standard treatment was USD $5,946 per quality adjusted life year gained. The ICER remained below the cost-effectiveness threshold in sub-group analyses. 97% of sensitivity analysis simulations showed an ICER below the cost-effectiveness threshold. CONCLUSION: From the perspective of the analysis, the addition of dapagliflozin to standard treatment is a cost-effective option in patients with heart failure with reduced ejection fraction in Colombia.
No takes yet. Share an insight, caveat, or question.
Gil-Rojas et al. (2021) studied heart failure with reduced ejection fraction. Dapagliflozin plus standard treatment vs. Standard treatment alone was evaluated on Incremental cost-effectiveness ratio (ICER) per quality adjusted life year gained.
Synapse has enriched 10 related papers. Consider them for comparative context: